Alkermes reported median ADHD symptom-score declines of 14 points at 20 mg per day and 19 at 50 mg per day after 14 days of split-dose ALKS 7290 in a 50-person adult trial. The Phase 1b study included placebo but did not establish benefit over it.
Safety and tolerability were the trial’s primary objectives. Alkermes reported no serious treatment-emergent adverse events or treatment-group discontinuations; common adverse events included insomnia, urinary symptoms and dizziness. The short trial cannot establish long-term safety or sustained symptom control.
An enrolling Phase 2 trial targets about 312 participants and will compare symptom-score changes with placebo at four weeks. Results are expected in 2027.
